Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06800963 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2025 to Oct 15, 2025 · Study sites: 2 to 9v4 Show 2 more changesShow less
    • Start date changed from estimate of May 2025 to Oct 15, 2025
    • Study sites: 2 to 9
  2. Start date: Feb 2025 to May 2025 Study sites: 0 to 2v3 Show 1 more changeShow less
    • Study sites: 0 to 2
  3. Eligibility criteria shortened, about 3 wordsv2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ImmunityBio, Inc.
33 trials monitored
See 2 trials at risk
Bladder Cancer
1,022 trials monitored
See 71 trials at risk
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (CIS) or have primary or recurrent stage Ta and/or T1 papillary tumors following Transurethral resection.
Trial Details
NCT Number NCT06800963
Lead Sponsor ImmunityBio, Inc.
Conditions NMIBC
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov